🏟️ Competitive War Room

Ada Patient Finder · Generated 2026-02-09T03:01

Threat Overview

CompetitorThreat LevelCategoryGong MentionsDeals at Risk
Medidata ●●●●● Clinical Trial Technology 350 0
OpenAI Muse ●●●●○ AI Trial Recruitment 28 0
IQVIA ●●●●○ Data Analytics / CRO 52 0
Tempus AI ●●●○○ Precision Medicine / Genomics 0 0
Flatiron Health ●●●○○ Oncology Data / Real-World Evidence 4 0
Komodo Health ●●●○○ Patient Journey Analytics 42 0
Veeva Systems ●●○○○ Pharma CRM & Data 0 0
PicnicHealth ●●○○○ Patient Records Platform 6 0

Competitor Details

Medidata

Threat 5/5

Dassault Systèmes · Clinical Trial Technology

Highest threat due to M&A interest (potential acquirer or competitor), massive pharma installed base, and resources of Dassault. Can bundle Patient Finder-like features into existing contracts.

What They Do

End-to-end clinical trial platform (Rave). EDC, CTMS, ePRO, site payments, decentralized trials. Largest clinical trial tech platform by market share.

🎯 Differentiation Talking Points

  1. Ada reaches patients directly through its symptom checker — Medidata only reaches them through sites/CROs
  2. Patient Finder identifies undiagnosed patients; Medidata works with already-diagnosed populations
  3. Ada's AI is patient-facing and builds trust; Medidata is infrastructure (invisible to patients)
  4. Medidata is a legacy platform — slow to innovate vs Ada's AI-native approach
  5. M&A interest from Medidata/Dassault validates Ada's value — use carefully in negotiations

🎙️ Gong Mentions (350)

OpenAI Muse

Threat 4/5

OpenAI (with Sanofi + Formation Bio) · AI Trial Recruitment

OpenAI brand + Sanofi resources make this a serious long-term threat. However, Muse is early and lacks Ada's patient-side engagement moat.

What They Do

AI-powered clinical trial design and patient recruitment. Sanofi partnership uses LLMs to optimize protocol design, site selection, and patient matching for trials.

🎯 Differentiation Talking Points

  1. Ada has a symptom-assessment engine with 13M+ users — real patient engagement, not just data mining
  2. Patient Finder works from the patient side (bottom-up) vs Muse working from the pharma protocol side (top-down)
  3. Ada's medical knowledge graph is purpose-built for differential diagnosis, not adapted from a general LLM
  4. Ada has existing relationships with health systems and payers — distribution Muse lacks
  5. Muse is early-stage; Ada Patient Finder is in-market with pharma clients

🎙️ Gong Mentions (28)

IQVIA

Threat 4/5

Independent (Public: IQV) · Data Analytics / CRO

Massive data moat and existing pharma relationships. Can bundle patient-finding into CRO contracts. However, lacks Ada's real-time patient engagement and undiagnosed patient identification.

What They Do

World's largest health data company. Claims data, Rx data, EHR data, CRO services. Serves pharma across R&D and commercial. $15B+ revenue.

🎯 Differentiation Talking Points

  1. IQVIA uses retrospective claims/Rx data; Ada uses real-time symptom data from active patients
  2. Ada finds UNDIAGNOSED patients — IQVIA's data only sees patients after they've entered the healthcare system
  3. Ada's patient engagement creates a direct relationship; IQVIA is purely data analytics
  4. IQVIA is a slow-moving giant; Ada is agile, AI-native, and can iterate faster
  5. IQVIA's data is US/EU claims; Ada has global patient reach through its app

🎙️ Gong Mentions (52)

Tempus AI

Threat 3/5

Independent (Public: TEM) · Precision Medicine / Genomics

Strong in oncology but limited overlap outside it. Public company with resources but different patient identification approach. More partner than threat.

What They Do

Genomic sequencing + clinical data platform. Uses AI to match patients to therapies and trials based on molecular profiling. Strong oncology focus. IPO'd 2024.

🎯 Differentiation Talking Points

  1. Ada catches patients BEFORE diagnosis (symptom stage); Tempus works POST-diagnosis (genomic stage)
  2. Ada is disease-agnostic; Tempus is oncology-heavy — Ada wins in rare disease, cardiology, neurology
  3. Patient Finder doesn't require a biopsy or lab test — lower barrier to patient identification
  4. Ada's 13M+ user base provides scale Tempus can't match outside oncology
  5. Complementary more than competitive: Ada finds suspects, Tempus confirms with genomics

Flatiron Health

Threat 3/5

Roche · Oncology Data / Real-World Evidence

Strong oncology moat but Roche ownership limits cross-pharma adoption. Narrow therapeutic focus reduces competitive overlap with Ada's broad approach.

What They Do

Oncology-focused EHR and real-world data platform. Curates structured clinical data from community oncology practices. Roche acquired for $1.9B in 2018.

🎯 Differentiation Talking Points

  1. Flatiron is oncology-only; Ada Patient Finder works across all therapeutic areas
  2. Ada reaches patients before they're in an oncology EHR — earlier in the patient journey
  3. Flatiron is Roche-owned, creating conflicts with other pharma; Ada is independent
  4. Patient Finder's AI-driven symptom analysis finds undiagnosed patients Flatiron can't see
  5. Flatiron's data is US community oncology; Ada is global (190+ countries)

🎙️ Gong Mentions (4)

Komodo Health

Threat 3/5

Independent (Private) · Patient Journey Analytics

Strong patient journey analytics but retrospective by nature. Can't identify undiagnosed patients, which is Ada's core differentiator.

What They Do

Healthcare map of 330M+ US patients from claims data. Patient journey analytics, treatment patterns, and trial feasibility. Used by pharma for commercial and clinical strategy.

🎯 Differentiation Talking Points

  1. Komodo maps PAST patient journeys from claims; Ada identifies patients in REAL-TIME via symptoms
  2. Ada catches patients before their first claim — the undiagnosed population Komodo can't see
  3. Patient Finder provides a patient engagement layer; Komodo is analytics-only
  4. Ada's AI-driven differential diagnosis adds clinical intelligence Komodo lacks
  5. Komodo is US-only; Ada is global

🎙️ Gong Mentions (42)

Veeva Systems

Threat 2/5

Independent (Public: VEEV) · Pharma CRM & Data

Different value prop (HCP vs patient focus). Veeva could build/buy patient-finding but hasn't prioritized it. More likely partner than competitor.

What They Do

Cloud software for pharma: CRM (field sales), Vault (content/regulatory), clinical data management. De facto standard for pharma commercial operations.

🎯 Differentiation Talking Points

  1. Veeva is HCP-focused (doctor targeting); Ada is patient-focused (patient identification)
  2. Patient Finder works upstream of Veeva — finds patients who then flow into Veeva-tracked HCP interactions
  3. Ada's symptom AI creates a unique data asset Veeva can't replicate from claims/Rx data
  4. Veeva is a platform play; Ada is a point solution with deep AI — different buying centers
  5. Integration opportunity: Patient Finder insights flowing into Veeva CRM for field teams

PicnicHealth

Threat 2/5

Independent (Private) · Patient Records Platform

Interesting patient-consent model but much smaller scale than Ada. More complementary than competitive — could be a data partner.

What They Do

Collects and structures patient medical records (with consent) to create longitudinal health data. Partners with pharma for real-world evidence and patient registries.

🎯 Differentiation Talking Points

  1. Ada has 13M+ users vs PicnicHealth's smaller patient panel
  2. Patient Finder uses AI symptom analysis; PicnicHealth aggregates existing records
  3. Ada identifies patients at symptom onset; PicnicHealth requires existing medical records
  4. Ada's approach is proactive (finds undiagnosed); PicnicHealth is passive (collects records of diagnosed)
  5. PicnicHealth's records are rich but slow to collect; Ada provides real-time patient signals

🎙️ Gong Mentions (6)

Ada Health · Competitive Intelligence · Confidential